ClinicalTrials.gg
RecruitingNCT07377032Updated Jan 29, 2026

TAP-GRIN: Interventional Study on Patients With GRIN-related Neurodevelopmental Disorders

A Phase 3 interventional study of L-serine and Maltodextrin (Placebo) in GRIN-related Disorders, GRIN1 and GRIN2A, sponsored by Meyer Children's Hospital IRCCS. Recruiting at 3 sites in 3 countries. Open to participants aged 2 Years to 30 Years. Per ClinicalTrials.gov, last updated 2026-01-29.

Sponsored by Meyer Children's Hospital IRCCS · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Aug 2025, registered Jan 2026).
  • Started Aug 2025; still recruiting 1 year 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
2 Years to 30 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 253 studies in Epilepsy with a site in France — 62 open to participants now, 70 under way, 8 of them phase 3. Epilepsy · France.

Planned enrollment
134th of 175
40 · median 100
Started
2025
with 16 others
Phase 3
65 of 253
5 open now
Primary completion
2028-06
later than 50 of 69 live
Registered
244th of 253
by date

Among the 253 studies in Epilepsy with a site in France, this one is the 134th largest by planned enrollment of the 175 interventional ones that give a count, is one of 17 that started in 2025, is one of 65 in phase 3, reaches primary completion later than 50 of the 69 other live ones, and was the 244th registered.

Epilepsy

1,850 studies on the registry are indexed under Epilepsy; 418 are open to participants now.

Browse Epilepsy studies →

Open to participants now

62 of the 253 studies in Epilepsy with a site in France are open now. Recruiting first, the newest first:

56 more — sign in →

All 62 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 284 Epilepsy studies recruiting now, 113 (40%) set no upper age limit and 148 (52%) stop at 75 or younger; 138 take children under 18; 54 take healthy volunteers.

This study: 2 Years to 30 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 253 studies in Epilepsy with a site in France, or all of them as a file.
02

Study summary

The goal of this clinical study is to find out whether L-serine dietary supplementation helps improve overall clinical functioning in children and young adults (2-30 years) with GRIN-related neurodevelopmental disorders (GRIN-NDD) caused by loss-of-function (LoF) variants in GRIN1, GRIN2A, GRIN2B, or GRIN2D. It will also assess the safety and tolerability of L-serine.

The main questions it aims to answer are:

Does L-serine improve overall clinical status, measured mainly by the Clinical Global Impression-Severity (CGI-S) score?

Does L-serine improve behaviour, cognition, adaptive functioning, motor skills, sleep, and (in those with epilepsy) seizure frequency and EEG findings?

What side effects or medical problems occur during L-serine compared with placebo?

Do neurophysiological measures (including TMS-EMG/TMS-EEG) change with treatment and potentially act as biomarkers of response?

Researchers will compare L-serine to a placebo (maltodextrin powder with similar appearance/texture) using a randomised, double-blind, placebo-controlled "n-of-1" approach, where each participant receives both treatments in alternating periods. Results from multiple single-patient trials will then be combined (aggregated) to estimate the overall treatment effect across the study population.

Participants will:

Complete a 4-week baseline period with assessments (and seizure diary use where applicable)

Receive L-serine and placebo in alternating 3-month periods within each cycle (minimum 2 cycles, up to 4 cycles; each cycle lasts 6 months)

Take the assigned study product by mouth 3 times per day at 500 mg/kg/day (maximum 30 g/day for participants ≥60 kg)

Have the first 7 days of each 3-month period treated as washout, with data from that week not analysed

Attend regular clinic visits for clinical exams, safety labs, and standardized assessments of global status, behaviour/cognition, motor function, and sleep

If they have epilepsy: keep a seizure diary and undergo EEG assessments after each treatment period

In some sites (Italy and France): undergo TMS-based neurophysiology testing

Optionally, a subset may join a cellular biomarker substudy (blood collection to generate iPSC-derived neuronal models and organoids) to explore treatment effects in variant-specific lab models.

Read the detailed description

GRIN-related neurodevelopmental disorders (GRIN-NDD) are rare genetic conditions caused by pathogenic variants in GRIN1, GRIN2A, GRIN2B, or GRIN2D, which encode subunits of the N-methyl-D-aspartate receptor (NMDAR). NMDARs play a central role in synaptic transmission, plasticity, and neurodevelopment. Variants affecting these genes may result in altered receptor function, most commonly loss of function (LoF), leading to a spectrum of neurodevelopmental phenotypes that include epilepsy, intellectual disability, behavioural abnormalities, sleep disturbances, and motor impairment.

Preclinical and clinical evidence suggests that enhancement of NMDAR co-agonist availability may partially restore receptor function in individuals with LoF GRIN variants. L-serine, a naturally occurring amino acid, serves as a metabolic precursor of D-serine, a major endogenous NMDAR co-agonist. Oral L-serine supplementation has been associated with clinical improvement in small case series and early-phase clinical studies involving individuals with GRIN-NDD due to LoF variants. However, systematic evidence from randomised, blinded studies remains limited, particularly given the rarity and phenotypic heterogeneity of these disorders.

This study is designed to evaluate the clinical effect and safety of L-serine supplementation using an aggregated series of randomised, double-blind, placebo-controlled n-of-1 trials. The n-of-1 approach allows each participant to serve as their own control and is well suited to rare diseases with substantial inter-individual variability. By aggregating data from multiple single-patient trials using Bayesian hierarchical models, the study aims to provide both individual-level and population-level estimates of treatment effect.

Following a baseline observation period, participants will undergo repeated treatment cycles in which L-serine supplementation and placebo are administered in alternating periods. Each cycle consists of two treatment periods of equal duration, with the order of treatments randomised for each cycle. A short washout interval is incorporated at the start of each treatment period to minimise potential carry-over effects. Both participants and investigators remain blinded to treatment allocation throughout the study, except in cases of emergency unblinding for safety reasons.

L-serine and placebo are provided as oral powders for solution and are administered at a fixed weight-based dose divided into three daily administrations. No dose titration is planned. Concomitant treatments, including antiseizure medications and other standard therapies, are permitted and remain stable whenever clinically feasible. Participants are monitored longitudinally through scheduled visits that include clinical evaluations, safety laboratory testing, and protocol-specified assessments.

The primary focus of the study is the assessment of global clinical change associated with L-serine supplementation compared with placebo. Secondary evaluations examine treatment effects across multiple functional domains, including behaviour, cognition, adaptive functioning, motor abilities, sleep quality, and, in participants with epilepsy, seizure frequency and electroencephalographic (EEG) features. These assessments are conducted repeatedly at the end of each treatment period, enabling within-subject comparisons across treatment conditions.

In addition to clinical outcomes, the study incorporates neurophysiological assessments to explore objective biomarkers of treatment response. Transcranial magnetic stimulation (TMS) combined with electromyography (EMG) and electroencephalography (EEG) is used at selected sites to characterise cortical excitability, inhibitory and excitatory balance, and network-level responses to stimulation. These measures are intended to provide mechanistic insights into NMDAR-related cortical function and to identify potential biomarkers that correlate with clinical response to L-serine.

An optional preclinical biomarker substudy is included for a subset of participants who provide additional consent. In this substudy, peripheral blood samples are used to generate induced pluripotent stem cells (iPSCs), which are subsequently differentiated into neuronal cell models and, in selected cases, three-dimensional brain organoids. These patient-derived models are used to examine neuronal development, synaptic function, network activity, and plasticity in vitro, and to assess the effects of L-serine exposure at the cellular and molecular levels. Data from this substudy are exploratory and are intended to support translational interpretation of clinical findings.

Safety monitoring is conducted throughout the study in accordance with Good Clinical Practice principles. Adverse events are systematically collected and evaluated for severity and potential relationship to the study product. Predefined criteria are in place for treatment discontinuation and early withdrawal in the event of clinical worsening or safety concerns. Given the non-pharmacological classification of L-serine as a food for special medical purposes and its prior clinical use, no specific toxicity signals are anticipated; however, ongoing monitoring is implemented to ensure participant safety.

The study is conducted across multiple international centres with expertise in GRIN-NDD. The innovative design of aggregated n-of-1 trials is intended to maximise the interpretability of results in a rare disease context, allowing identification of both average treatment effects and inter-individual variability in response. The findings are expected to inform clinical decision-making, contribute to evidence-based use of L-serine in GRIN-NDD, and support the broader application of n-of-1 trial methodologies in rare neurological disorders.

03

Conditions studied

  • GRIN-related Disorders
  • GRIN1
  • GRIN2A
  • GRIN2B
  • GRIN2D
  • Epilepsy
  • Neurodevelopmental Disorder (Diagnosis)
04

Who can participate

Ages eligible
2 Years to 30 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical diagnosis of a GRIN-related neurodevelopmental disorder (GRIN-NDD)
  • Presence of a pathogenic or likely pathogenic loss-of-function (LoF) variant in GRIN1, GRIN2A, GRIN2B, or GRIN2D
  • Parent(s), caregiver(s), or legally authorised representative(s) have been informed of the nature of the study and have provided written .
  • Participants who are able to do so have provided written informed consent or assent, according to local regulations and cognitive capacity.
  • Parent(s)/caregiver(s) are willing and able to comply with study procedures and visits, in the opinion of the investigator.
  • Participants who have previously received L-serine supplementation are willing to discontinue L-serine for at least one week prior to the baseline observation period.

Exclusion criteria

Exclusion Criteria:

  • Age younger than 2 years at screening.
  • Known or intolerance to L-serine, placebo, or any used in the study formulations.
  • Presence of a unstable medical condition (other than epilepsy) that, in the investigator's judgement, may place the participant at increased risk or interfere with study participation.
  • Any other significant disease or disorder that may compromise participant safety, affect study outcomes, or impair the participant's ability to complete the study procedures.
  • Inadequate supervision by parent(s) or caregiver(s), as judged by the investigator.
  • Participation in another clinical trial involving an medicinal product within the previous 6 months.
  • Female participants who are pregnant or breastfeeding.
  • Presence of a GRIN1, GRIN2A, GRIN2B, or GRIN2D variant for which a clear loss-of-function effect cannot be demonstrated.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
40 participants (estimated)

Study arms

  • Active comparator
    Experimental group

    L-serine supplementation is administered as an oral powder for solution and used as an add-on intervention to participants' existing standard of care. L-serine is a naturally occurring amino acid and is classified as a food for special medical purposes. In this study, L-serine is used to increase the availability of its enantiomer D-serine, an endogenous co-agonist of the N-methyl-D-aspartate receptor (NMDAR), with the aim of enhancing NMDAR-mediated neurotransmission in individuals with GRIN-related neurodevelopmental disorders caused by loss-of-function variants. The intervention is delivered using a randomised, double-blind, placebo-controlled n-of-1 design, in which each participant receives both L-serine and placebo in alternating treatment periods. L-serine and placebo are identical in appearance, packaging, and method of administration to maintain blinding. Treatment allocation within each cycle is determined by a computer-generated randomisation schedule managed by unblinded

    Dietary Supplement: L-serine

  • Placebo comparator
    Placebo

    Placebo is administered as an oral powder for solution and serves as the comparator to L-serine supplementation. The placebo consists primarily of maltodextrin, a readily digestible carbohydrate that is commonly used as an inert control substance in clinical studies. It is classified as a food-grade product and contains no active amino acids or pharmacologically active ingredients. The placebo is formulated to be indistinguishable from L-serine with respect to appearance, texture, solubility, and method of administration, in order to maintain blinding of participants, caregivers, investigators, and study staff. Packaging, labelling, and dosing instructions are identical to those used for the active intervention. The placebo is administered orally in three divided daily doses, following the same dosing schedule and duration as the active intervention within the randomised, double-blind, n-of-1 trial design. Each placebo treatment period lasts three months, with the first seven days d

    Other: Maltodextrin (Placebo)

Interventions

  • Dietary supplementSerineStudies of SerineSerine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    L-serine supplementation is administered as an oral powder for solution and used as an add-on intervention to participants' existing standard of care. L-serine is a naturally occurring amino acid and is classified as a food for special medical purposes. In this study, L-serine is used to increase the availability of its enantiomer D-serine, an endogenous co-agonist of the N-methyl-D-aspartate receptor (NMDAR), with the aim of enhancing NMDAR-mediated neurotransmission in individuals with GRIN-related neurodevelopmental disorders caused by loss-of-function variants. The intervention is delivered using a randomised, double-blind, placebo-controlled n-of-1 design, in which each participant receives both L-serine and placebo in alternating treatment periods. L-serine and placebo are identical in appearance, packaging, and method of administration to maintain blinding. Treatment allocation within each cycle is determined by a computer-generated randomisation schedule managed by unblinded s

  • OtherMaltodextrin (Placebo)

    Placebo is administered as an oral powder for solution and serves as the comparator to L-serine supplementation. The placebo consists primarily of maltodextrin, a readily digestible carbohydrate that is commonly used as an inert control substance in clinical studies. It is classified as a food-grade product and contains no active amino acids or pharmacologically active ingredients. The placebo is formulated to be indistinguishable from L-serine with respect to appearance, texture, solubility, and method of administration, in order to maintain blinding of participants, caregivers, investigators, and study staff. Packaging, labelling, and dosing instructions are identical to those used for the active intervention. The placebo is administered orally in three divided daily doses, following the same dosing schedule and duration as the active intervention within the randomised, double-blind, n-of-1 trial design. Each placebo treatment period lasts three months, with the first seven days de

06

What researchers measure

Primary outcomes

  1. Change in Clinical Global Impression - Severity (CGI-S) score

    The Clinical Global Impression - Severity (CGI-S) scale is a clinician-rated measure of overall illness severity. The primary outcome is the within-subject difference in CGI-S score comparing L-serine supplementation with placebo, assessed at the end of each treatment period relative to baseline. Lower CGI-S scores indicate less severe overall clinical status.

    Time frame: From baseline to the end of each 3-month treatment period, assessed repeatedly across all completed treatment cycles (minimum 2 cycles, up to 4 cycles; total study duration up to approximately 104 weeks).

Secondary outcomes

  1. Number of adverse events

    Safety and tolerability will be assessed through the collection of adverse events (AEs), serious adverse events (SAEs), clinical examinations, vital signs, body weight, neurological examinations, and laboratory parameters during L-serine and placebo periods.

    Time frame: From baseline through the end of the last treatment period and the 2-week post-treatment safety follow-up (up to approximately 110 weeks).

  2. Change in Clinical Global Impression - Improvement (CGI-I) score

    The CGI-I is a clinician-rated measure of overall improvement or worsening compared with baseline. Changes in CGI-I scores will be compared between L-serine and placebo treatment periods within subjects.

    Time frame: Assessed at the end of each 3-month treatment period across all completed treatment cycles (minimum 2 cycles, up to 4 cycles; up to approximately 104 weeks)

  3. Change in behavioural functioning

    Behavioural changes will be assessed using age-appropriate standardized instruments (Child Behavior Checklist \[CBCL\] or Adult Behavior Checklist \[ABCL\]). Scores obtained at the end of each treatment period will be compared with baseline and between L-serine and placebo periods.

    Time frame: From baseline to the end of each 3-month treatment period across all completed treatment cycles (up to approximately 104 weeks).

  4. Change in adaptive functioning

    Adaptive functioning will be assessed using standardized measures (Vineland Adaptive Behavior Scales \[VABS\] or Adaptive Behaviour Assessment System, Third Edition \[ABAS-3\], as appropriate). Changes from baseline will be compared between treatment conditions.

    Time frame: From baseline to the end of each 3-month treatment period across all completed treatment cycles (up to approximately 104 weeks).

  5. Change in cognitive performance

    Cognitive performance will be evaluated using EpiTrack Junior or EpiTrack, depending on participant age. Changes in total and subscale scores will be compared between L-serine and placebo treatment periods.

    Time frame: From baseline to the end of each 3-month treatment period across all completed treatment cycles (up to approximately 104 weeks).

  6. Change in motor function

    Motor function will be assessed using the Manual Ability Classification System (MACS) and, when feasible, the Movement Assessment Battery for Children - Second Edition (MABC-2). Changes from baseline will be compared across treatment periods.

    Time frame: From baseline to the end of each 3-month treatment period across all completed treatment cycles (up to approximately 104 weeks).

  7. Change in sleep quality

    Sleep quality will be assessed using standardized questionnaires (Pittsburgh Sleep Quality Index \[PSQI\] and/or age-appropriate sleep questionnaires). Changes from baseline will be compared between L-serine and placebo periods

    Time frame: From baseline to the end of each 3-month treatment period across all completed treatment cycles (up to approximately 104 weeks).

  8. Change in seizure frequency (epilepsy subgroup)

    For participants with epilepsy, seizure frequency will be assessed using caregiver-completed seizure diaries. Percentage change in seizure frequency per 28 days will be compared between L-serine and placebo treatment periods.

    Time frame: From baseline to the end of each 3-month treatment period across all completed treatment cycles (up to approximately 104 weeks).

  9. Change in epileptiform discharge frequency on EEG (epilepsy subgroup)

    Standard EEG recordings will be evaluated by expert review using a participant-specific scoring system (worsened, unchanged, or improved). EEG changes will be compared between L-serine and placebo periods.

    Time frame: From baseline to the end of each 3-month treatment period across all completed treatment cycles (up to approximately 104 weeks).

  10. Change in neurophysiological biomarkers (TMS-EMG / TMS-EEG)

    Neurophysiological measures derived from transcranial magnetic stimulation combined with EMG and EEG will be analysed to assess changes in cortical excitability, inhibition/facilitation balance, and network-level responses.

    Time frame: From baseline to the end of each 3-month treatment period across all completed treatment cycles (up to approximately 104 weeks).

07

Study locations

2 of 3 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Jun 2028, 34 months after the start.

Of 86 phase 3 interventional studies under Epilepsy, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 69. This study's planned 34 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 19, 2026
First posted
Jan 29, 2026
StartActual
Aug 29, 2025
Primary completionEst.
Jun 2028
CompletionEst.
Jun 2028
Last update
Jan 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07377032
Lead sponsor
Meyer Children's Hospital IRCCS
Responsible party
Simona Balestrini (MD, Meyer Children's Hospital IRCCS) — Principal investigator
First posted
Jan 29, 2026
Start date
Aug 29, 2025
Primary completion
Jun 2028 (estimated)
Completion
Jun 2028 (estimated)
Last update
Jan 29, 2026

Study contacts

Simona Balestrini, Md, PhD
Contact
simona.balestrini@meyer.it
00390555662719

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Serine

Start the discussion